Certara (NASDAQ:CERT) is a global biosimulation company that plays a pivotal role in the acceleration of drug discovery and development. It specializes in creating software and services that support decision-making processes of the biopharmaceutical and healthcare sectors. The company's range of projects encompasses regulatory science, drug development, and the application of quantitative systems pharmacology (QSP) to increase the efficiency and success rate of bringing new therapies to market. Certara's objectives are closely tied to improving human health through innovation, reducing the time and cost associated with drug development, and enhancing decision-making in complex scenarios. This approach not only benefits the pharmaceutical industry but also aims to have a direct positive impact on patient outcomes.